Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Thyroid Gland Medullary Carcinoma

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Thyroid Gland Medullary Carcinoma cohort.

Asset / SponsorPhaseRating
Cediranib
Vanderbilt-Ingram Cancer Center
Phase 2B
Everolimus
National Cancer Institute (NCI)
Phase 1CCC
Temsirolimus
University of Southern California
Phase 1CC
Sargramostim
National Cancer Institute (NCI)
Phase 1CC
Octreotide Pamoate
National Cancer Institute (NCI)
Phase 1CC

View all 20 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Metastases, NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →